{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"340.2","value":"359.4"}]}],"title":"Prior to vaccine administration (Week 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"190.3","value":"12893.2"}]}],"title":"Prior to vaccine booster (Week 4)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5717.1","value":"208.9"}]}],"title":"After vaccine booster (Week 8)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"CXCL11 (C-X-C motif chemokine 11) protein concentration levels measures in peripheral blood. Increased levels can be predictive of good prognosis.","dispersionType":"Standard Deviation","groups":[{"description":"α DC1 vaccine\n\nand\n\nChemokine Modulatory Regimen:\n\nCelecoxib: Administered at 200 mg, once a day orally (T-TH) Rintatolimod: Intravenous infusion of 200 mg (Wed \\& and Fri, only) Interferon Alfa-2b: Intravenous infusion - 5 MU/m\\^2 or 20 MU/m\\^2 (T-Fri)","id":"OG000","title":"α DC1 Vaccine + Chemokine Modulatory Regimen"}],"paramType":"MEAN","populationDescription":"Patients treated with at least 1 course of α DC1 vaccine + 1 cycle of chemokine modulatory regimen who were evaluable for completing surgery and response to treatment, and with ≥80% of samples available with measurable cytokine profiles via peripheral blood assay.","reportingStatus":"POSTED","timeFrame":"Prior to vaccine administration (Week 1), prior to vaccine booster (Week 4) and after vaccine booster (Week 8)","title":"CXCL11 (C-X-C Motif Chemokine 11) Levels","type":"SECONDARY","unitOfMeasure":"pg/mL"}